JPRN-jRCT2080221942未知1 期
A PHASE I / II TRIAL OF WEEKLY ABI-007 PLUS GEMCITABINE IN PATIENTS WITH METASTIC PANCREATIC CANCER
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients must be diagnosed as invasive ductal carcinoma.
- •-Patient must have received no previous therapy.
- •-Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- •-Written informed consent.
排除标准
- •- Patient has pre-existing peripheral neuropathy or symptoms of peripheral sensory.
- •- Patient has uncontrollable pain symptoms.
- •- Patient has uncontrolled or severe diabetes.
- •- Patient has complication or history of serious lung disease, serious heart disease, serious cerebrovascular disorder, or other serious diseases.
研究者
相似试验
未知
1 期
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast CancerMetastatic breast cancerJPRN-jRCT2080221553Taiho Pharmaceutical Co., Ltd.24
进行中（未招募）
1 期
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114
进行中（未招募）
不适用
ENSAYO EN FASE I/II DE LA COMBINACIÓN DE GEMCITABINA EN INFUSIÓN PROLONGADA Y PACLITAXEL ADMINISTRADOS DE FORMA QUINCENAL EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE MAMA AVANZADOEUCTR2004-004148-34-ESDr. José Ignacio Chacón López-Muñiz
进行中（未招募）
不适用
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
进行中（未招募）
1 期
A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung CancerPreviously Untreated Extensive Stage Small Cell Lung Cancer (SCLC)MedDRA version: 13.1 Level: LLT Classification code 10041067 Term: Small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003292-42-GBAmgen Inc213